BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (IM), a competitive inhibitor capable to bind to the ATP pocket in the kinase domain of BCR-ABL1 protein, was the first TKI used in CML therapy, with over 95% of response rates [20,21].